Artículo
Immune response to racotumomab in a child with relapsed neuroblastoma
Sampor, Claudia; Guthmann, M. D.; Scursoni, A.; Cacciavillano, Walter; Torbidoni, Ana Vanesa
; Galluzzo, L.; Camarero, S.; Lopez, J.; de Dávila, M. T. G.; Fainboim, Leonardo
; Chantada, Guillermo Luis
Fecha de publicación:
12/2012
Editorial:
Frontiers in Oncology
Revista:
Frontiers in Oncology
ISSN:
2234-943X
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
Immunotherapy targeting ganglioside antigens is a powerful tool for the treatment of high risk neuroblastoma. However, only treatment with anti-GD2 antibodies has been used in clinical practice and other options may be pursued. We report the use of racotumomab, an anti-idiotype vaccine against N-glycolyl neuraminic acid (NeuGc)- containing gangliosides, eliciting an immune response in a child with relapsed neuroblastoma expressing the NeuGcGM3 ganglioside.
Palabras clave:
Immunotherapy
,
Monoclonal Antibodies
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(INIGEM)
Articulos de INSTITUTO DE INMUNOLOGIA, GENETICA Y METABOLISMO
Articulos de INSTITUTO DE INMUNOLOGIA, GENETICA Y METABOLISMO
Citación
Sampor, Claudia; Guthmann, M. D.; Scursoni, A.; Cacciavillano, Walter; Torbidoni, Ana Vanesa; et al.; Immune response to racotumomab in a child with relapsed neuroblastoma; Frontiers in Oncology; Frontiers in Oncology; 2; 12-2012; 10-20
Compartir
Altmétricas